ArticleApoptosis : an international journal on programmed cell death2025
Integrative analysis of RiboSis-related gene expression in colorectal cancer: implications for prognosis and immunotherapy.
Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Preliminary revelation of potential therapeutic targets related to ribosome biogenesis in lung adenocarcinoma based on bioinformatics analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- PFDN2 stabilizes PYCR2 to activate Wnt/β-catenin signaling and promote colorectal cancer progression.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) is a prevalent and lethal malignancy that imposes significant burdens on patients and healthcare systems worldwide. This study aimed to explore the significance of ribosome biogenesis (RiboSis)-related genes (RRGs) in CRC and their clinical implications. The scRNA-seq data of three CRC tissues were sourced from the Gene Expression Omnibus (GEO) database. Nonnegative matrix factorization (NMF) was employed to categorize cell subtypes associated with RiboSis. An integrative machine learning approach encompassing ten algorithms was subsequently implemented to develop a prognostic signature. Our research revealed 295 differentially expressed RiboSis-related genes (DERRGs) associated with survival outcomes, with a notable RiboSis score that was markedly higher in CRC tissues than in normal counterparts. Univariate Cox analysis revealed 25 DERRGs with significant survival differences (P < 0.05). scRNA-seq of 26,961 cells from 13 CRC samples revealed eight major cell types, with T and B cells predominantly enriched in immune response pathways. InferCNV analysis distinguished malignant epithelial cells on the basis of copy number variations, and NMF identified four RiboSis-related cell subtypes. Our RiboSis-related prognostic model, validated across the TCGA, GSE17536, and GSE39582 datasets, demonstrated high predictive accuracy. Notably, low RiboSis signature scores were correlated with reduced immune evasion risk and upregulated immune checkpoint genes, suggesting enhanced responsiveness to immunotherapy. Among the 8 model genes, PFDN2 was considered the hub gene. The experimental results of PFDN2 in this RiboSis signature indicated that PFDN2 expression is elevated in CRC tissues and that PFDN2 knockdown promotes the proliferation, migration, and invasion of CRC cells. This study underscores the potential of RRGs as biomarkers and therapeutic targets, offering new avenues for personalized CRC management.
Indexed as
Identifiers
40839324What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.